Sonnet BioTherapeutics (SONN) Competitors $9.77 +0.13 (+1.35%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$9.56 -0.21 (-2.10%) As of 07:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. HLVX, TCRX, SAVA, ANIX, CRBP, COYA, HURA, CTNM, ZNTL, and MGNXShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include HilleVax (HLVX), TScan Therapeutics (TCRX), Cassava Sciences (SAVA), Anixa Biosciences (ANIX), Corbus Pharmaceuticals (CRBP), Coya Therapeutics (COYA), TuHURA Biosciences (HURA), Contineum Therapeutics (CTNM), Zentalis Pharmaceuticals (ZNTL), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Its Competitors HilleVax TScan Therapeutics Cassava Sciences Anixa Biosciences Corbus Pharmaceuticals Coya Therapeutics TuHURA Biosciences Contineum Therapeutics Zentalis Pharmaceuticals MacroGenics HilleVax (NASDAQ:HLVX) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability. Which has preferable valuation and earnings, HLVX or SONN? Sonnet BioTherapeutics has higher revenue and earnings than HilleVax. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHilleVaxN/AN/A-$147.27M-$2.15-0.99Sonnet BioTherapeutics$20K1,548.55-$7.44MN/AN/A Does the media prefer HLVX or SONN? In the previous week, Sonnet BioTherapeutics had 12 more articles in the media than HilleVax. MarketBeat recorded 15 mentions for Sonnet BioTherapeutics and 3 mentions for HilleVax. HilleVax's average media sentiment score of 1.37 beat Sonnet BioTherapeutics' score of 0.44 indicating that HilleVax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HilleVax 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sonnet BioTherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, HLVX or SONN? HilleVax has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Do analysts prefer HLVX or SONN? HilleVax currently has a consensus price target of $2.00, indicating a potential downside of 6.10%. Sonnet BioTherapeutics has a consensus price target of $20.00, indicating a potential upside of 104.71%. Given Sonnet BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HilleVax 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of HLVX or SONN? 86.4% of HilleVax shares are held by institutional investors. Comparatively, 9.5% of Sonnet BioTherapeutics shares are held by institutional investors. 24.9% of HilleVax shares are held by company insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is HLVX or SONN more profitable? HilleVax's return on equity of -51.86% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HilleVaxN/A -51.86% -41.45% Sonnet BioTherapeutics N/A -777.92%-271.32% SummarySonnet BioTherapeutics beats HilleVax on 7 of the 12 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.52M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.2228.5419.58Price / Sales1,548.55299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book-13.767.568.145.54Net Income-$7.44M-$55.11M$3.24B$257.73M7 Day Performance110.56%3.81%0.18%-0.08%1 Month Performance735.04%11.60%5.96%8.09%1 Year Performance40.54%-2.11%26.24%13.02% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics3.7511 of 5 stars$9.77+1.3%$20.00+104.7%+38.4%$30.52M$20K0.0010Trending NewsGap DownHigh Trading VolumeHLVXHilleVax2.0755 of 5 stars$2.13-1.8%$2.00-6.1%+21.7%$107.05MN/A-0.9920Positive NewsTCRXTScan Therapeutics3.5522 of 5 stars$1.88-2.1%$7.80+314.9%-75.1%$106.39M$4.42M-1.72100SAVACassava Sciences4.272 of 5 stars$2.19+1.2%$54.50+2,394.3%-83.3%$105.56MN/A-1.4630Positive NewsANIXAnixa Biosciences2.92 of 5 stars$3.23+0.9%$9.00+178.6%-0.6%$104.04M$210K-8.505News CoverageCRBPCorbus Pharmaceuticals4.2975 of 5 stars$8.49+2.7%$50.88+499.2%-86.4%$104.02MN/A-2.0140News CoverageCOYACoya Therapeutics1.9444 of 5 stars$6.19+1.0%$16.50+166.6%-21.4%$103.61M$3.69M-5.796HURATuHURA Biosciences1.3698 of 5 stars$2.37+1.5%$12.67+435.4%N/A$103.35MN/A0.00N/ACTNMContineum Therapeutics3.65 of 5 stars$3.91-0.2%$22.50+475.2%-82.0%$100.76M$50M-1.9831News CoveragePositive NewsHigh Trading VolumeZNTLZentalis Pharmaceuticals2.4733 of 5 stars$1.38+1.4%$8.37+506.7%-66.3%$99.22M$67.43M-0.44160News CoveragePositive NewsMGNXMacroGenics4.3133 of 5 stars$1.59-1.0%$5.71+258.5%-69.2%$98.80M$152.43M-1.76430 Related Companies and Tools Related Companies HilleVax Competitors TScan Therapeutics Competitors Cassava Sciences Competitors Anixa Biosciences Competitors Corbus Pharmaceuticals Competitors Coya Therapeutics Competitors TuHURA Biosciences Competitors Contineum Therapeutics Competitors Zentalis Pharmaceuticals Competitors MacroGenics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SONN Stock Alerts